- Home
- NDMO vs CRMD Comparison
NDMO vs CRMD Comparison
Compare NDMO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- CRMD
- Stock Information
- Founded
- NDMO 2019
- CRMD 2006
- Country
- NDMO United States
- CRMD United States
- Employees
- NDMO N/A
- CRMD 82
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- CRMD Health Care
- Exchange
- NDMO Nasdaq
- CRMD Nasdaq
- Market Cap
- NDMO 620.6M
- CRMD 865.2M
- IPO Year
- NDMO N/A
- CRMD 2010
- Fundamental
- Price
- NDMO $10.37
- CRMD $11.12
- Analyst Decision
- NDMO
- CRMD Strong Buy
- Analyst Count
- NDMO 0
- CRMD 8
- Target Price
- NDMO N/A
- CRMD $17.57
- AVG Volume (30 Days)
- NDMO 218.6K
- CRMD 4.6M
- Earning Date
- NDMO 01-01-0001
- CRMD 10-29-2025
- Dividend Yield
- NDMO 6.75%
- CRMD N/A
- EPS Growth
- NDMO N/A
- CRMD N/A
- EPS
- NDMO N/A
- CRMD 0.79
- Revenue
- NDMO N/A
- CRMD $121,484,498.00
- Revenue This Year
- NDMO N/A
- CRMD $404.81
- Revenue Next Year
- NDMO N/A
- CRMD $56.11
- P/E Ratio
- NDMO N/A
- CRMD $14.00
- Revenue Growth
- NDMO N/A
- CRMD 14970.29
- 52 Week Low
- NDMO $8.99
- CRMD $5.60
- 52 Week High
- NDMO $11.24
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- NDMO 68.92
- CRMD 34.64
- Support Level
- NDMO $10.36
- CRMD $12.73
- Resistance Level
- NDMO $9.98
- CRMD $13.83
- Average True Range (ATR)
- NDMO 0.12
- CRMD 0.81
- MACD
- NDMO 0.04
- CRMD -0.30
- Stochastic Oscillator
- NDMO 84.72
- CRMD 1.03
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.